Terms: = Kidney tumors AND MAX, MGC36767, 4149, ENSG00000125952, MGC18164, MGC10775, P61244, MGC11225, orf1, MGC34679 AND Prognosis
15 results:
1. Prognostic significance of 18F-FDG PET/CT indices in metastatic renal cell cancer and evaluation of revised IMDC risk model by including 18F-FDG PET-CT parameters.
Arikan R; Ozguven S; Telli TA; Isik S; Demircan NC; Basoglu T; Yasar A; Celebi A; Filizoglu N; Ustun HS; Tinay I; Ones T; Turoglu HT; Erdil TY; Ozturk MA; Ercelep O; Bayoglu V; Kostek O; Dane F; Yumuk PF
Acta Radiol; 2023 May; 64(5):2040-2049. PubMed ID: 36447438
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic importance of SUVmax values evaluated by 18F-FDG-PET/CT before nivolumab treatment in patients with metastatic renal cell carcinoma.
Gulturk I; Yilmaz M; Tacar SY; Tural D
Q J Nucl Med Mol Imaging; 2023 Sep; 67(3):223-229. PubMed ID: 34881845
[TBL] [Abstract] [Full Text] [Related]
3. The Role of FDG-PET and Whole-Body MRI in High Grade Bone Sarcomas With Particular Focus on Osteosarcoma.
Farina A; Gasperini C; Aparisi Gómez MP; Bazzocchi A; Fanti S; Nanni C
Semin Nucl Med; 2022 Sep; 52(5):635-646. PubMed ID: 34879906
[TBL] [Abstract] [Full Text] [Related]
4. Lesion detection by [
Verhoeff SR; van Es SC; Boon E; van Helden E; Angus L; Elias SG; Oosting SF; Aarntzen EH; Brouwers AH; Kwee TC; Heskamp S; Hoekstra OS; Verheul H; van der Veldt AAM; de Vries EGE; Boerman OC; van der Graaf WTA; Oyen WJG; van Herpen CML
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1931-1939. PubMed ID: 31172212
[TBL] [Abstract] [Full Text] [Related]
5. Long-term oncological outcomes of cystic renal cell carcinoma according to the Bosniak classification.
Boissier R; Ouzaid I; Nouhaud FX; Khene Z; Dariane C; Chkir S; Chelly S; Giwerc A; Allenet C; Lefrancq JB; Gimel P; Bodin T; Rioux-Leclercq N; Correas JM; Albiges L; Hetet JF; Bigot P; Bernhard JC; Long JA; Mejean A; Bensalah K;
Int Urol Nephrol; 2019 Jun; 51(6):951-958. PubMed ID: 30977021
[TBL] [Abstract] [Full Text] [Related]
6. FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma.
Nakaigawa N; Kondo K; Kaneta T; Tateishi U; Minamimoto R; Namura K; Ueno D; Kobayashi K; Kishida T; Ikeda I; Hasumi H; Makiyama K; Hayashi N; Osaka K; Muraoka K; Izumi K; Kawahara T; Teranishi JI; Miyoshi Y; Yumura Y; Uemura H; Inoue T; Yao M
Cancer Chemother Pharmacol; 2018 Apr; 81(4):739-744. PubMed ID: 29464355
[TBL] [Abstract] [Full Text] [Related]
7. Management of bilateral Wilms tumours.
Millar AJW; Cox S; Davidson A
Pediatr Surg Int; 2017 Jul; 33(7):737-745. PubMed ID: 28516188
[TBL] [Abstract] [Full Text] [Related]
8. The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy.
Nakaigawa N; Kondo K; Ueno D; Namura K; Makiyama K; Kobayashi K; Shioi K; Ikeda I; Kishida T; Kaneta T; Minamimoto R; Tateishi U; Inoue T; Yao M
BMC Cancer; 2017 Jan; 17(1):39. PubMed ID: 28068944
[TBL] [Abstract] [Full Text] [Related]
9. Management of bilateral Wilms tumours.
Millar AJ; Cox S; Davidson A
Pediatr Surg Int; 2017 Apr; 33(4):461-469. PubMed ID: 28054101
[TBL] [Abstract] [Full Text] [Related]
10. FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma.
Nakaigawa N; Kondo K; Tateishi U; Minamimoto R; Kaneta T; Namura K; Ueno D; Kobayashi K; Kishida T; Ikeda I; Hasumi H; Makiyama K; Kubota Y; Inoue T; Yao M
BMC Cancer; 2016 Feb; 16():67. PubMed ID: 26857818
[TBL] [Abstract] [Full Text] [Related]
11. Management of bilateral Wilms tumor over three decades: The perspective of a single center.
User IR; Ekinci S; Kale G; Akyüz C; Büyükpamukçu M; Karnak I; Çiftçi AÖ; Tanyel FC; Şenocak ME
J Pediatr Urol; 2015 Jun; 11(3):118.e1-6. PubMed ID: 25842994
[TBL] [Abstract] [Full Text] [Related]
12. 18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation.
Ferda J; Ferdova E; Hora M; Hes O; Finek J; Topolcan O; Kreuzberg B
Anticancer Res; 2013 Jun; 33(6):2665-72. PubMed ID: 23749925
[TBL] [Abstract] [Full Text] [Related]
13. Pilot study of F(18)-Fluorodeoxyglucose Positron Emission Tomography/computerised tomography in Wilms' tumour: correlation with conventional imaging, pathology and immunohistochemistry.
Begent J; Sebire NJ; Levitt G; Brock P; Jones KP; Ell P; Gordon I; Anderson J
Eur J Cancer; 2011 Feb; 47(3):389-96. PubMed ID: 21074411
[TBL] [Abstract] [Full Text] [Related]
14. The lack of correlation between mast cells and microvessel density with pathologic feature of renal cell carcinoma.
Mohseni MG; Mohammadi A; Heshmat AS; Kosari F; Meysamie AP
Int Urol Nephrol; 2010 Mar; 42(1):109-12. PubMed ID: 19449120
[TBL] [Abstract] [Full Text] [Related]
15. Treatment of Wilms' tumour. Current recommendations.
Mehta MP; Bastin KT; Wiersma SR
Drugs; 1991 Nov; 42(5):766-80. PubMed ID: 1723373
[TBL] [Abstract] [Full Text] [Related]
